Wegovy vs Mounjaro Labels and the Head-to-Head Trial

Wegovy is semaglutide labeled for weight management, and Mounjaro is tirzepatide labeled for type 2 diabetes. In the SURMOUNT-5 trial of adults with obesity and without type 2 diabetes, the least-squares mean weight change at week 72 was -20.2% with tirzepatide and -13.7% with semaglutide.⁴ A physician matches the label to your condition, your health history, and your lab results. Understanding how these medications differ helps you evaluate your options before your medical consultation.

Primary Label Differences Between Wegovy and Mounjaro

The primary difference between Wegovy and Mounjaro centers on their active ingredients and approved regulatory indications.

When you look at these two brand-name medications, you see different molecules approved for distinct clinical conditions. Your physician considers your primary diagnosis, your metabolic health, and your cardiovascular status before deciding which prescription matches your needs.

Wegovy contains semaglutide, which functions as a glucagon-like peptide-1 (GLP-1) receptor agonist.² The Food and Drug Administration (FDA) approved Wegovy subcutaneous injection to reduce excess body weight and maintain long-term weight reduction in adults and pediatric patients aged 12 years and older with obesity.² It is also indicated for adults with overweight who have at least one weight-related comorbid condition.²

Beyond weight management, Wegovy injection is approved to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight.² Under accelerated approval, Wegovy injection is also indicated for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis in adults.² Furthermore, Wegovy tablets are indicated for long-term weight reduction and cardiovascular-risk reduction in adults.² Limitations in the prescribing information state that concomitant use of Wegovy with other semaglutide products or any other GLP-1 receptor agonist is not recommended.²

Mounjaro contains tirzepatide, a single molecule that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors.¹ The FDA approved Mounjaro as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.¹ Mounjaro is also indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who are at high risk for these events.¹

The indications section of the Mounjaro label does not list weight management.¹ If your goal is weight reduction without a diagnosis of type 2 diabetes, Mounjaro does not carry an on-label indication for your treatment. Instead, Eli Lilly markets tirzepatide under the brand name Zepbound for chronic weight management.³

Approved Indications for Tirzepatide Under the Zepbound Label

Because Mounjaro and Zepbound share the identical active ingredient, understanding the separate branding helps you navigate your prescription options.^1,3 While Mounjaro is labeled specifically for glycemic control in type 2 diabetes, Zepbound is the tirzepatide product approved for chronic weight management.^1,3

The FDA approved Zepbound in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain long-term weight reduction in adults with obesity, or adults with overweight in the presence of at least one weight-related comorbid condition.³ Zepbound is also indicated to treat moderate to severe obstructive sleep apnea in adults with obesity.³

Just like Wegovy, the Zepbound label specifies that coadministration with other tirzepatide products or any other GLP-1 receptor agonist is not recommended.³ If your physician determines that tirzepatide fits your health profile for weight management or sleep apnea, your prescription will reflect the Zepbound label rather than Mounjaro.^1,3 You can review our comparative analysis of how Zepbound and Mounjaro are the same ingredient to understand how these two brand names function in clinical practice.

Head-to-Head Comparison in the SURMOUNT-5 Trial

The SURMOUNT-5 clinical trial directly compared the active ingredients in these medications in adults with obesity who do not have type 2 diabetes.⁴ Conducted as a phase 3b, open-label, randomized controlled study, the trial enrolled 751 participants across multiple research centers.⁴ Investigators randomly assigned participants in a 1:1 ratio to receive either maximum tolerated tirzepatide (10 mg or 15 mg) or maximum tolerated semaglutide (1.7 mg or 2.4 mg) subcutaneously once weekly for 72 weeks.⁴

These milligram numbers reflect the specific doses evaluated in this research study. They do not constitute a dosing recommendation for your personal care, and they do not serve as a dose-conversion chart between products. Your physician determines your specific starting dose and titration schedule based on your individual tolerance and clinical response.

At the conclusion of the 72-week trial period, researchers observed clear differences in physical measurements between the two groups.⁴ The least-squares mean percent change in body weight at week 72 was -20.2% (95% confidence interval [CI], -21.4 to -19.1) with tirzepatide compared to -13.7% (95% CI, -14.9 to -12.6) with semaglutide (P<0.001).⁴

Waist circumference measurements followed a similar trajectory. Participants receiving tirzepatide achieved a least-squares mean reduction of -18.4 cm (95% CI, -19.6 to -17.2), whereas participants receiving semaglutide achieved a reduction of -13.0 cm (95% CI, -14.3 to -11.7) (P<0.001).⁴ Among participants with obesity but without diabetes, treatment with tirzepatide proved superior to semaglutide with respect to reduction in body weight and waist circumference at week 72.⁴

The trial was funded by Eli Lilly and registered under ClinicalTrials.gov number NCT05822830.⁴ The published trial abstract evaluated the active pharmaceutical ingredients and did not evaluate the medications under the commercial brand names Mounjaro, Wegovy, or Zepbound.⁴

Clinical Limits and Excluded Populations in the Study

The SURMOUNT-5 trial answered a specific research question, but its findings do not apply to every health situation you or your doctor might face.⁴ When you evaluate medical evidence, identifying who was excluded from a study is just as informative as reading the headline numbers.

The trial excluded adults with type 2 diabetes mellitus.⁴ If you have type 2 diabetes, the -20.2% and -13.7% weight changes do not apply to you. The trial did not enroll that population. Mounjaro versus Ozempic is the comparison written for the diabetes labels.

The trial enrolled only adult participants.⁴ It did not evaluate pediatric or adolescent patients. While Wegovy injection holds approval for pediatric patients aged 12 and older with obesity, and Mounjaro is approved for pediatric patients aged 10 and older with type 2 diabetes, SURMOUNT-5 provides no pediatric comparative data.^1,2,4

The trial protocol did not evaluate switching from one medication to the other.⁴ The study evaluated participants assigned to a single therapy over 72 weeks. It did not report prior GLP-1 receptor agonist exposure and did not assess how a patient responds when transitioning from semaglutide to tirzepatide or vice versa.⁴ If you are currently taking semaglutide and considering a change, the trial does not provide a roadmap or switching protocol for your transition.

SURMOUNT-5 did not assess other approved indications, such as cardiovascular event reduction, MASH with liver fibrosis, or obstructive sleep apnea.⁴ If your health profile includes cardiovascular disease or liver fibrosis, Wegovy holds specific labeled indications that the SURMOUNT-5 data do not address.^2,4 Similarly, if you suffer from obstructive sleep apnea alongside obesity, Zepbound carries an approved indication that was not measured in this head-to-head trial.^3,4

Your physician must weigh your full spectrum of health conditions rather than relying solely on a single trial endpoint. You can read more about how these indications differ in our direct analysis of the SURMOUNT-5 weight result in our comparison of Zepbound and Wegovy.

Adverse Reaction Profiles and Cross-Trial Comparisons

Both semaglutide and tirzepatide affect gastrointestinal motility, leading to similar types of physical side effects during therapy.^1,2 In the SURMOUNT-5 trial, researchers reported that the most common adverse events in both treatment arms were gastrointestinal.⁴ Most of these events were mild to moderate in severity, and they occurred primarily during dose escalation.⁴

When you review the manufacturer prescribing information for Wegovy and Mounjaro, you will see lists of reported adverse reactions. However, both package inserts state an important clinical principle: adverse reaction rates observed in clinical trials of one drug cannot be directly compared with rates from clinical trials of another drug.¹ Differences in study design, patient populations, dose-escalation protocols, and monitoring methods prevent reliable head-to-head percentage comparisons outside of direct trials.

On the Wegovy label, adverse reactions reported with an incidence of at least 5% include nausea, diarrhea, vomiting, constipation, abdominal pain, dysesthesia, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, flatulence, gastroenteritis, gastroesophageal reflux disease, and hair loss.² In patients with type 2 diabetes taking Wegovy, hypoglycemia is also reported in at least 5% of patients.²

On the Mounjaro label, the most common adverse reactions reported in at least 5% of patients treated with tirzepatide include nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain.¹

Both labels list the same thyroid contraindication. The labels say not to use Wegovy or Mounjaro if you have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.^1,2 The labels also say not to use them if you have a known serious hypersensitivity to the active ingredient or to any of the excipients.^1,2 Your physician uses that history at intake.

Medication Pricing and Pharmacy Dispensing Realities

Neither the Wegovy prescribing information nor the Mounjaro prescribing information publishes retail pharmacy prices, copay rates, or cash costs.^1,2 Drug manufacturers establish list prices that differ significantly from what you might pay at a retail pharmacy counter or through an outpatient clinic.

This page does not have a pharmacy price for either brand. The amount you pay can differ from a list price, and this page does not itemize that difference. Ozempic versus Wegovy separates the two semaglutide brand names.

To explore verified out-of-pocket numbers, self-pay ranges, and cash pricing dynamics across incretin therapies, consult our guide on what Wegovy and Zepbound list as self-pay. Working with your physician allows you to identify the appropriate molecule before you examine pharmacy purchasing options.

The Opt Take on Wegovy and Mounjaro

The brand names do not tell a physician which label fits you. Opt Health starts with a blood panel of 55+ biomarkers, taken at home or at a local partner lab. A physician reviews that panel with you in a one-to-one consult, including your symptoms and your history. If a GLP-1 medicine is part of the plan, the physician matches the molecule to the labeled use.

The membership includes follow-up testing. Every 3 to 4 months the physician repeats the panel and reviews the plan with you.

Get started: Begin with Opt Health, where a physician reads your labs, builds your plan, and adjusts it over the loop.

Frequently Asked Questions

This content is for informational purposes and does not replace evaluation, diagnosis, or treatment by a qualified medical professional.